The prevalence of hypercholesterolaemia (hc) &amp; related clinical features in insulin dependent diabetes mellitus (IDDM)

Winocour, PH; Durrington, Paul N.; Ishola, M.; Anderson, D.C.; Cohen, H.

doi:10.1016/0021-9150(87)90214-0

Cited by 10 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of hypercholesterolaemia in the present study was similar to that found in the Wisconsin Study (46%) [36] and by Winocour et al . [37]. In the EURODIAB Study, 45% of patients had LDL‐C levels > 3.35 mmol/L, which is associated with an increased cardiovascular risk in adults with diabetes [38], but 86% of women and 69% of men had HDL‐C levels > 1.15 mmol/L, which is considered to be a low‐risk category [38].…”

Section: Discussionmentioning

confidence: 99%

Factors associated with plasma lipids and lipoproteins in Type 1 diabetes mellitus: the EURODIAB IDDM Complications Study

et al. 2001

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Factors associated with plasma lipids and lipoproteins in Type 1 diabetes mellitus: the EURODIAB IDDM Complications Study

et al. 2001

View full text Add to dashboard Cite

show abstract

“…The prevalence of hypercholesterolemia in IDDM women was slightly higher than that in men (13 vs. 8%, respectively). However, because some studies do not reveal significant excess of dyslipidemia in IDDM women (16,17), other risk factors may be contributing to the excess of atherosclerosis in IDDM women. The true prevalence of dyslipidemia in IDDM patients, however, should be higher because older patients (>40 years of age), those with proteinuria, or those with a longer duration of diabetes were excluded.…”

Section: Dyslipidemia-mentioning

confidence: 97%

Management of Dyslipidemia in IPPM Patients

Garg

1994

Diabetes Care

View full text Add to dashboard Cite

Patients with insulin-dependent diabetes mellitus (IDDM) are at an increased risk for coronary heart disease. Factors that may enhance the risk include dyslipidemia, hypertension, and hyperglycemia. Until recently, the importance of dyslipidemia in IDDM was ignored because the prevalence of high cholesterol levels was similar to that in the nondiabetic population. However, unique abnormalities in the composition and metabolism of lipoproteins may occur in IDDM patients. Management of IDDM patients, therefore, should include control of dyslipidemia as well as control of hyperglycemia and hypertension. The therapeutic goals for serum cholesterol reduction in IDDM patients should be lower than that for nondiabetic patients, and the goals for children should be even lower than those for adults. Both very-low-density lipoprotein and low-density lipoprotein (LDL) levels should be the targets for therapeutic interventions and not just the LDL alone. Because of the unique features of dyslipidemia in IDDM patients, the therapeutic options may not be the same as that for nondiabetic patients. Hyperglycemia should be controlled by matching daily energy intake and activity with appropriately timed doses of insulin. The diets should be low in saturated fats and cholesterol. If dyslipidemia persists despite diet and hyperglycemia management, drug therapy may be initiated. For IDDM children > or = 10 years of age with elevated LDL-cholesterol levels, the first-line therapy should be bile acid sequestrants. For adults with IDDM, bile acid sequestrants also may be the drugs of choice, particularly for normotriglyceridemic patients. Nicotinic acid therapy should be avoided. Among other drugs, hydroxymethyl-glutaryl coenzyme A reductase inhibitors may be preferable for patients with elevated LDL cholesterol and borderline hypertriglyceridemia. Fibric acid derivatives should be used for markedly hypertriglyceridemic patients. The role of probucol for dyslipidemia in IDDM patients is not clear.

show abstract

“…Little data exists on lipoproteins and CHD in patients with type 1 diabetes mellitus. As noted above, dyslipidaemia in well‐controlled type 1 diabetes mellitus is not more common than in the general population[14–16], although there may be subtle abnormalities in the composition of circulating lipoproteins[14]. However, in many patients with type 1 diabetes development of nephropathy leads to dyslipidaemia with elevated levels of total and low density lipoprotein (LDL) cholesterol, elevated triglycerides and low levels of high density lipoprotein (HDL)‐cholesterol.…”

Section: Dyslipidaemia and Cardiovascular Risk In Type 1 Diabetes Melmentioning

confidence: 99%

Dyslipidaemia and cardiovascular risk in diabetes

Cullen

Eckardstein

Souris³

et al. 1999

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

The prevalence of hypercholesterolaemia (hc) & related clinical features in insulin dependent diabetes mellitus (IDDM)

Cited by 10 publications

References 0 publications

Factors associated with plasma lipids and lipoproteins in Type 1 diabetes mellitus: the EURODIAB IDDM Complications Study

Factors associated with plasma lipids and lipoproteins in Type 1 diabetes mellitus: the EURODIAB IDDM Complications Study

Management of Dyslipidemia in IPPM Patients

Dyslipidaemia and cardiovascular risk in diabetes

Contact Info

Product

Resources

About